101 Svr4 and Svr12 With an Interferon-Free Regimen of Bi201335 and Bi207127, +/- Ribavirin, in Treatment-Naive Patients With Chronic Genotype-1 HCV Infection: Interim Results of Sound-C2

Zeuzem, Stefan; Soriano, Vincent; Asselah, Tarik; Bronowicki, Jean–Pierre; Lohse, Ansgar W.; Müllhaupt, Beat; Schuchmann, M.; Bourlière, Marc; Buti, Marı́a; Roberts, Stuart K.; Gane, Edward; Stern, Jerry O.; Kukolj, George; Dai, Lili; Böcher, Wulf O.; Mensa, Federico

doi:10.1016/s0168-8278(12)60115-9

Cited by 65 publications

(49 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, an impact of IL28B genetic variations has been observed under interferon-based triple therapy [10][11][12] in treatment-naive patients. It also seems to play a role in interferon-free regimens [43,44], particularly with specific combinations [44]. Therefore, the value of genomic predictors is likely to remain important in the setting of DAA-based therapy.…”

Section: Discussionmentioning

confidence: 99%

Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection

Neukam

Caruz

Rivero‐Juárez

et al. 2013

Aids

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection

Neukam

Caruz

Rivero‐Juárez

et al. 2013

Aids

View full text Add to dashboard Cite

show abstract

“…Currently, many clinical studies are ongoing that evaluate the use of DAA combinations in the treatment of HCV-infected patients. In particular, the combination of a protease inhibitor and an NNI with ribavirin has shown clinical efficacy in HCV-infected patients with high rates of rapid virologic response and SVR, especially in genotype 1b-infected patients (46). SPR enabled delineation of the kinetics of TMC647055 binding to multiple NS5B⌬C21 polymerase clinical isolates and isolates with site-directed mutations.…”

Section: Discussionmentioning

confidence: 99%

TMC647055, a Potent Nonnucleoside Hepatitis C Virus NS5B Polymerase Inhibitor with Cross-Genotypic Coverage

Devogelaere

Berke

Vijgen

et al. 2012

Antimicrob Agents Chemother

View full text Add to dashboard Cite

ABSTRACTHepatitis C virus (HCV) infection is a major global health burden and is associated with an increased risk of liver cirrhosis and hepatocellular carcinoma. There remains an unmet medical need for efficacious and safe direct antivirals with complementary modes of action for combination in treatment regimens to deliver a high cure rate with a short duration of treatment for HCV patients. Here we report thein vitroinhibitory activity, mode of action, binding kinetics, and resistance profile of TMC647055, a novel and potent nonnucleoside inhibitor of the HCV NS5B RNA-dependent RNA polymerase.In vitrocombination studies with an HCV NS3/4A protease inhibitor demonstrated potent suppression of HCV RNA replication, confirming the potential for combination of these two classes in the treatment of chronic HCV infection. TMC647055 is a potent nonnucleoside NS5B polymerase inhibitor of HCV replication with a promisingin vitrobiochemical, kinetic, and virological profile that is currently undergoing clinical evaluation.

show abstract

“…23 This study included arms with the NS3 protease inhibitor BI201335 and the NS5B nonnucleoside inhibitor BI207127 with or without ribavirin for treatment durations from 16 to 40 weeks. Like other recent studies, the study suggested that ribavirin was important to the regimen, and patients with genotype 1b were more likely to achieve SVR than patients with genotype 1a.…”

Section: (%) Ct (%) Tt (%)mentioning

confidence: 99%

IL28B in the Era of Direct-acting Antivirals for Hepatitis C

Muir¹

2013

Journal of Clinical Gastroenterology

View full text Add to dashboard Cite

The IL28B genotype is the strongest baseline predictor of hepatitis C treatment response with peginterferon-α and ribavirin. In 2011, 2 protease inhibitors were approved for genotype 1 infection in combination with peginterferon-α and ribavirin, and boceprevir and telaprevir attenuate the association between the IL28B genotype and treatment response. Although sustained virologic response rates are improved for all IL28B genotypes with the addition of the protease inhibitors, the unfavorable IL28B genotypes have substantial benefit. IL28B also predicts the likelihood of shortened duration of treatment with the protease inhibitor combination. As hepatitis C treatment moves towards interferon-free regimens, the role of IL28B in these regimens is under investigation.

show abstract

101 Svr4 and Svr12 With an Interferon-Free Regimen of Bi201335 and Bi207127, +/- Ribavirin, in Treatment-Naive Patients With Chronic Genotype-1 HCV Infection: Interim Results of Sound-C2

Cited by 65 publications

References 0 publications

Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection

Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection

TMC647055, a Potent Nonnucleoside Hepatitis C Virus NS5B Polymerase Inhibitor with Cross-Genotypic Coverage

IL28B in the Era of Direct-acting Antivirals for Hepatitis C

Contact Info

Product

Resources

About